Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Influenza
Studies from University of Massachusetts provide new data on influenza
November 26th, 2008
"Among 17 HLA-A2-positive healthy adults, CD8(+) T-cell responses against an HLA-A2-restricted matrix protein 1 (M1) epitope increased after immunization with trivalent inactivated influenza vaccine (TIV) in two individuals," researchers in the United States report. "The presence of M1 in TIV was confirmed by Western blotting. T-cell cytotoxicity assays showed that TIV is processed and the epitope is presented by antigen-presenting cells to an M1 epitope-specific CD8(+) T-cell line for specific lysis," wrote M. Terajima and colleagues, University of Massachusetts. The researchers concluded: "These data show that TIV, which is formulated to contain...
Source: Vaccine Weekly (2008-11-26)
|
